<DOC>
	<DOCNO>NCT00228163</DOCNO>
	<brief_summary>The primary objective ass long-term safety teriflunomide multiple sclerosis subject . The secondary objective ass long-term efficacy .</brief_summary>
	<brief_title>Long Term Safety Efficacy Teriflunomide ( HMR1726 ) Multiple Sclerosis With Relapses</brief_title>
	<detailed_description>Subjects complete HMR 1726D/2001 study give opportunity continue switch teriflunomide 528 week teriflunomide commercially available country patient live ; - subject Teriflunomide 7 mg 14 mg continue dose teriflunomide . - subject placebo randomize teriflunomide 7 mg 14 mg . The total study period per subject 532 week teriflunomide commercially available country patient life , broken follow : - Treatment : 528 week teriflunomide commercially available country patient life , - Post-washout follow-up : 4 week last treatment intake .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Satisfactorily completion HMR1726D/2001 study respect safety . If female subject , nonchildbearing potential child bear potential adequate contraception . Consent practice/maintain adequate mean contraception throughout study 24 month discontinuation treatment . Clinically definite Multiple Sclerosis ( MS ) establish entry HMR1726D/2001 study . Extended Disability Status Score ( EDSS ) 0 6 inclusively , subject enter HMR1726D/2001 study . Magnetic Resonance Imaging ( MRI ) criterion must continue support diagnosis clinically definite MS . Willingness participate longterm safety efficacy trial . Subject complete HMR 1726D/2001 study safety reason . Subject develop clinically relevant cardiovascular , hepatic , endocrine major disease . Pregnancy . Breastfeeding . Wish parent . Likelihood require treatment study period drug permit . Disallowed therapy asw immunomodulators , immunosuppressant . Recent history drug alcohol abuse . Liver function impairment . Abnormal mental condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Multiple Sclerosis Relapsing Remitting</keyword>
	<keyword>Secondary Progressive</keyword>
	<keyword>Progressive Relapsing</keyword>
</DOC>